相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Using germline genotype in cancer pharmacogenetic studies
Sarah R. McWhinney et al.
PHARMACOGENOMICS (2009)
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
L. Pare et al.
BRITISH JOURNAL OF CANCER (2008)
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients
Rohini Sharma et al.
CLINICAL CANCER RESEARCH (2008)
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy
Marie-Christine Etienne-Grimaldi et al.
CLINICAL CANCER RESEARCH (2008)
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
Eva Martinez-Balibrea et al.
EUROPEAN JOURNAL OF CANCER (2008)
Bleomycin in testicular cancer: Will pharmacogenomics improve treatment regimens?
Carsten Bokemeyer
JOURNAL OF CLINICAL ONCOLOGY (2008)
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741
Hanna K. Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A. Ruzzo et al.
PHARMACOGENOMICS JOURNAL (2008)
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer
O. Capitain et al.
PHARMACOGENOMICS JOURNAL (2008)
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer
Marie-Christine Etienne-Grimaldi et al.
PHARMACOGENOMICS (2007)
Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
George P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Kwang Wook Suh et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: Importance of an increased neutrophil count
Michael Michael et al.
CLINICAL COLORECTAL CANCER (2006)
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity
Paul L. Mitchell et al.
CLINICAL COLORECTAL CANCER (2006)
Polymorphisms in genes of nucleotide and base excision repair:: Risk and prognosis of colorectal cancer
V Moreno et al.
CLINICAL CANCER RESEARCH (2006)
p53 and disease: when the guardian angel fails
J. A. Royds et al.
CELL DEATH AND DIFFERENTIATION (2006)
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
E Marcuello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA
S Marsh et al.
PHARMACOGENOMICS (2005)
The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation:: Influence of tumor site, type of mutation, and adjuvant treatment
A Russo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients
D Goldstein et al.
BRITISH JOURNAL OF CANCER (2005)
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
A Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer
ML Veronese et al.
EUROPEAN JOURNAL OF CANCER (2004)
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate
KJ Sohn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients
MC Etienne et al.
PHARMACOGENETICS (2004)
XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
J Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prognostic significance of microsatellite instability and ki-ras mutation type in stage II colorectal cancer
C Wang et al.
ONCOLOGY (2003)
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
H Elsaleh et al.
LANCET (2000)
Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism
B Iacopetta et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2000)
分享论文
